Please assess the completion status of the following clinical trial:

Trial Title: Study Of Two Non-Myeloablative Stem Cell Transplant Strategies For Low-Grade Lymphoma And CLL

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: None
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: None
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Diagnosis of chronic lymphocytic leukemia or~* Diagnosis of non-Hodgkin's lymphoma~* Lymphoplasmacytic lymphoma~* Grade I follicular small cleaved cell lymphoma~* Grade II follicular mixed cell lymphoma~* Diffuse small cleaved cell lymphoma~* Small lymphocytic lymphoma~* Relapsed after at least 1 course of prior therapy~* Availability of a 6/6 human leukocyte antigen (HLA) A, B, and DR identical sibling donor~* Nonmyeloablative transplantation candidate~* No clinically significant effusions or ascites that would preclude administration of methotrexate~PATIENT CHARACTERISTICS:~-Age: 18 to 75~Performance status:~* Eastern Cooperative Oncology Group (ECOG) 0-2 OR Zubrod 0-2~* Life expectancy: At least 6 months~* Hematopoietic: Not specified~* Hepatic: Bilirubin no greater than 3 mg/dL~* Renal: Creatinine no greater than 2 mg/dL~* Cardiovascular: left ventricular ejection fraction (LVEF) at least 40% on multigated acquisition (MUGA) scan or echocardiogram~* Pulmonary: diffusing capacity of lung for carbon monoxide (DLCO) at least 50% of predicted~OTHER:~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective contraception~* No uncontrolled bacterial, viral, fungal, or parasitic infection~* Human Immunodeficiency Virus (HIV)1 and Human Immunodeficiency Virus (HIV)2 negative~* No other active malignancy except basal cell skin cancer~* No recent history of drug or alcohol abuse~* No other primary disease or comorbid illness that would severely limit life expectancy~PRIOR CONCURRENT THERAPY~* Biologic therapy:See Disease Characteristics~* Biologic therapy:Prior autologous bone marrow transplantation allowed if disease has progressed after transplantation~* Biologic therapy:No entry on study as part of a tandem autologous transplantation followed by nonmyeloablative allograft protocol~* Chemotherapy: Not specified~* Endocrine therapy: Not specified~* Radiotherapy:Not specified~* Surgery: Not specified

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).